Literature DB >> 31395299

Effects of a Higher Heart Rate on Quality of Life and Functional Capacity in Patients With Left Ventricular Diastolic Dysfunction.

Kramer Wahlberg1, Maren E Arnold2, Daniel Lustgarten2, Markus Meyer2.   

Abstract

There is no evidence-based treatment for heart failure with preserved ejection fraction. Although lower heart rates (HRs) provide an unequivocal benefit for patients with HF with reduced ejection fraction, higher HR might convey important hemodynamic and substrate-modifying benefits in patients with diastolic dysfunction. In a prospective study of 20 stable outpatients with diastolic dysfunction and pacemakers, we evaluated the effects of a 4-week increase in the lower pacemaker rate to 80 beats/min followed by reversal to the previous lower HR setting from weeks 4 to 6. We assessed quality of life (Minnesota Living with Heart Failure Questionnaire), 6-minute walk test and N-terminal pro-brain natriuretic peptide (NT-proBNP) levels. Pacing at 80 beats/min significantly improved quality of life and the 6-minute walk test (p ≤0.05). There was a strong positive correlation between the pacing-induced changes in NT-proBNP and baseline QRS intervals (r2 = 0.31, p <0.01). Stratification by QRS duration revealed that pacing at 80 beats/min led to -21 ± 26% reduction in NT-proBNP in patients with QRS ≤150 ms, whereas QRS >150 ms was associated with a 26 ± 35% increase in NT-proBNP (p <0.01). Patients physiologically paced from the conduction system had a -46 ± 26% reduction in NT-proBNP at 80 beats/min as compared with 4 ± 26% and 13 ± 26% change with pacing from the right atrial appendage and right ventricular apical septum (pinteraction = 0.04). In conclusion, increasing the lower rate setting of pacemakers to 80 beats/min in patients with diastolic dysfunction improves quality of life, functional capacity, and NT-proBNP for those patients with a baseline QRS ≤150 ms. These findings suggest that higher HRs may provide meaningful benefits to patients with left ventricular diastolic dysfunction and heart failure with preserved ejection fraction.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31395299      PMCID: PMC6744960          DOI: 10.1016/j.amjcard.2019.07.008

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  30 in total

1.  Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.

Authors:  Bryan Williams; Peter S Lacy; Simon M Thom; Kennedy Cruickshank; Alice Stanton; David Collier; Alun D Hughes; H Thurston; Michael O'Rourke
Journal:  Circulation       Date:  2006-02-13       Impact factor: 29.690

Review 2.  Cardiac plasticity.

Authors:  Joseph A Hill; Eric N Olson
Journal:  N Engl J Med       Date:  2008-03-27       Impact factor: 91.245

3.  A meta-analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus.

Authors:  Sripal Bangalore; Sanobar Parkar; Ehud Grossman; Franz H Messerli
Journal:  Am J Cardiol       Date:  2007-08-10       Impact factor: 2.778

4.  Phospholamban: a major determinant of the cardiac force-frequency relationship.

Authors:  W F Bluhm; E G Kranias; W H Dillmann; M Meyer
Journal:  Am J Physiol Heart Circ Physiol       Date:  2000-01       Impact factor: 4.733

5.  Unexplained week-to-week variation in BNP and NT-proBNP is low in chronic heart failure patients during steady state.

Authors:  Morten Schou; Finn Gustafsson; Per H Nielsen; Lene H Madsen; Andreas Kjaer; Per R Hildebrandt
Journal:  Eur J Heart Fail       Date:  2006-07-07       Impact factor: 15.534

6.  Prevention of chronic atrial fibrillation by pacing in the region of Bachmann's bundle: results of a multicenter randomized trial.

Authors:  S J Bailin; S Adler; M Giudici
Journal:  J Cardiovasc Electrophysiol       Date:  2001-08

7.  Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

Authors:  Lars H Lindholm; Hans Ibsen; Björn Dahlöf; Richard B Devereux; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Stevo Julius; Sverre E Kjeldsen; Krister Kristiansson; Ole Lederballe-Pedersen; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel; Peter Aurup; Jonathan Edelman; Steven Snapinn
Journal:  Lancet       Date:  2002-03-23       Impact factor: 79.321

Review 8.  Resting heart rate in cardiovascular disease.

Authors:  Kim Fox; Jeffrey S Borer; A John Camm; Nicolas Danchin; Roberto Ferrari; Jose L Lopez Sendon; Philippe Gabriel Steg; Jean-Claude Tardif; Luigi Tavazzi; Michal Tendera
Journal:  J Am Coll Cardiol       Date:  2007-08-13       Impact factor: 24.094

9.  Role of left ventricular stiffness in heart failure with normal ejection fraction.

Authors:  Dirk Westermann; Mario Kasner; Paul Steendijk; Frank Spillmann; Alexander Riad; Kerstin Weitmann; Wolfgang Hoffmann; Wolfgang Poller; Matthias Pauschinger; Heinz-Peter Schultheiss; Carsten Tschöpe
Journal:  Circulation       Date:  2008-04-14       Impact factor: 29.690

10.  Relation of beta-blocker-induced heart rate lowering and cardioprotection in hypertension.

Authors:  Sripal Bangalore; Sabrina Sawhney; Franz H Messerli
Journal:  J Am Coll Cardiol       Date:  2008-10-28       Impact factor: 24.094

View more
  3 in total

1.  An approach towards individualized lower rate settings for pacemakers.

Authors:  Margaret Infeld; Robert Avram; Kramer Wahlberg; Daniel N Silverman; Nicole Habel; Daniel L Lustgarten; Mark J Pletcher; Jeffrey E Olgin; Gregory M Marcus; Markus Meyer
Journal:  Heart Rhythm O2       Date:  2020-10-06

2.  Personalized pacing for diastolic dysfunction and heart failure with preserved ejection fraction: Design and rationale for the myPACE randomized controlled trial.

Authors:  Margaret Infeld; Kramer Wahlberg; Jillian Cicero; Sean Meagher; Nicole Habel; Anand Muthu Krishnan; Daniel N Silverman; Daniel L Lustgarten; Markus Meyer
Journal:  Heart Rhythm O2       Date:  2021-12-07

3.  Heart Rate-Induced Myocardial Ca2+ Retention and Left Ventricular Volume Loss in Patients With Heart Failure With Preserved Ejection Fraction.

Authors:  Daniel N Silverman; Mehdi Rambod; Daniel L Lustgarten; Robert Lobel; Martin M LeWinter; Markus Meyer
Journal:  J Am Heart Assoc       Date:  2020-08-28       Impact factor: 5.501

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.